Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
40%(2 trials)

Phase Distribution

Ph phase_3
5
100%

Phase Distribution

0

Early Stage

0

Mid Stage

5

Late Stage

Phase Distribution5 total trials
Phase 3Large-scale testing
5(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 35 (100.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_3

A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)

NCT00132717
completedphase_3

Effectiveness of Two Approved Drugs in Lowering High Cholesterol (0733-224)

NCT00092157
completedphase_3

MK-0524B Lipid Study (MK-0524B-063)

NCT00479882
completedphase_3

Lipid Efficacy Study (0524B-022)(COMPLETED)

NCT00269217
completedphase_3

Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)

NCT00479388

Clinical Trials (5)

Showing 5 of 5 trials
NCT00132717Phase 3

A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)

Completed
NCT00092157Phase 3

Effectiveness of Two Approved Drugs in Lowering High Cholesterol (0733-224)

Completed
NCT00479882Phase 3

MK-0524B Lipid Study (MK-0524B-063)

Completed
NCT00269217Phase 3

Lipid Efficacy Study (0524B-022)(COMPLETED)

Completed
NCT00479388Phase 3

Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5